Abstract:In recent years, clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) protein have emerged as a revolutionary gene editing tool to treat inherited disorders affecting different organ systems, such as blood and muscles. Both hematological and neuromuscular genetic disorders benefit from genome editing approaches but face different challenges in their clinical translation. The ability of CRISPR/Cas9 technologies to modify hematopoietic stem cells ex vivo has greatly accelerated the development of genetic therapies for blood disorders. In the last decade, many clinical trials were initiated and are now delivering encouraging results. The recent FDA approval of Casgevy, the first CRISPR/Cas9-based drug for severe sickle cell disease and transfusion-dependent β-thalassemia, represents a significant milestone in the field and highlights the great potential of this technology. Similar preclinical efforts are currently expanding CRISPR therapies to other hematologic disorders such as primary immunodeficiencies. In the neuromuscular field, the versatility of CRISPR/Cas9 has been instrumental for the generation of new cellular and animal models of Duchenne muscular dystrophy (DMD), offering innovative platforms to speed up preclinical development of therapeutic solutions. Several corrective interventions have been proposed to genetically restore dystrophin production using the CRISPR toolbox and have demonstrated promising results in different DMD animal models. Although these advances represent a significant step forward to the clinical translation of CRISPR/Cas9 therapies to DMD, there are still many hurdles to overcome, such as in vivo delivery methods associated with high viral vector doses, together with safety and immunological concerns. Collectively, the results obtained in the hematological and neuromuscular fields emphasize the transformative impact of CRISPR/Cas9 for patients affected by these debilitating conditions. As each field suffers from different and specific challenges, the clinical translation of CRISPR therapies may progress differentially depending on the genetic disorder. Ongoing investigations and clinical trials will address risks and limitations of these therapies, including long-term efficacy, potential genotoxicity, and adverse immune reactions. This review provides insights into the diverse applications of CRISPR-based technologies in both preclinical and clinical settings for monogenic blood disorders and muscular dystrophy and compare advances in both fields while highlighting current trends, difficulties, and challenges to overcome.

Gene therapy and gene editing strategies in inherited blood disorders

Therapeutic Gene Editing for Hemoglobinopathies

[Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology]

Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders

Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects

Gene Therapies for Hemoglobinopathies: Promises and Challenges

A Review of Gene Therapies for Hemoglobinopathies

Highly efficient therapeutic gene editing of human hematopoietic stem cells

Comprehensive Update on Applications of CRISPR / Cas 9 for Hematological Diseases

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation

Gene Editing-Based Technologies for Beta-hemoglobinopathies Treatment

The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia

In vivo genome editing of human hematopoietic stem cells for treatment of blood disorders by mRNA delivery

Therapy Development by Genome Editing of Hematopoietic Stem Cells

CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments

CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β 0 /β 0 transfusion-dependent β-thalassemia

[Gene Editing Technology and Its Recent Progress in Disease Therapy].

Gene Therapy for Inherited Liver Disease: To Add or to Edit

Precise Somatic Genome Editing for Treatment of Inborn Errors of Immunity.